These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31379316)

  • 21. Oral treprostinil in the treatment of pulmonary arterial hypertension.
    Feldman J; Habib N; Radosevich J; Dutt M
    Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
    Kaufmann P; Okubo K; Bruderer S; Mant T; Yamada T; Dingemanse J; Mukai H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):195-203. PubMed ID: 25850750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum: A Retrospective Observational Case Series Study.
    Wang T; Lu J; Li Q; Chen Y; Ye Q; Gao J; Yang D; Zhao L; Huang J; Zhang J
    Anesth Analg; 2019 Dec; 129(6):1607-1612. PubMed ID: 31743181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease.
    Hall K; Ogawa M; Sakarovitch C; Hopper RK; Adamson GT; Hanna B; Ivy DD; Miller-Reed K; Yung D; McCarthy E; Siehr-Handler SL; Feinstein JA
    J Cardiovasc Pharmacol; 2019 Jun; 73(6):383-393. PubMed ID: 31162247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension.
    Sardana M; Moll M; Farber HW
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1513-1520. PubMed ID: 27756196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis.
    Manzi G; Mariani MV; Filomena D; Recchioni T; Papa S; Scoccia G; Badagliacca R; Vizza CD
    Vascul Pharmacol; 2024 Mar; 154():107280. PubMed ID: 38309551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inpatient Initiation of Oral Treprostinil in an Academic Medical System.
    Hohlfelder B; Tonelli AR; Heresi GA; Bair N; Rahaghi FF; Bauer SR
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):547-553. PubMed ID: 32424651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
    PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
    Gaine S; Sitbon O; Channick RN; Chin KM; Sauter R; Galiè N; Hoeper MM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Tapson V; Ghofrani HA; Lang I
    Chest; 2021 Jul; 160(1):277-286. PubMed ID: 33545163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension.
    Olsson KM; Richter MJ; Kamp JC; Gall H; Heine A; Ghofrani HA; Fuge J; Ewert R; Hoeper MM
    J Heart Lung Transplant; 2019 Jul; 38(7):748-756. PubMed ID: 31128966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selexipag for the treatment of pulmonary arterial hypertension.
    Genecand L; Wacker J; Beghetti M; Lador F
    Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
    Morrison K; Studer R; Ernst R; Haag F; Kauser K; Clozel M
    J Pharmacol Exp Ther; 2012 Dec; 343(3):547-55. PubMed ID: 22918043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry.
    Lachant D; Minkin R; Swisher J; Mogri M; Zolty R; Hwang S; Seaman S; Broderick M; Sahay S
    Pulm Pharmacol Ther; 2023 Oct; 82():102232. PubMed ID: 37451609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
    Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
    Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
    Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
    Demerouti EA; Karyofyllis P; Apostolopoulou SC
    Can J Cardiol; 2021 Aug; 37(8):1286-1288. PubMed ID: 33539988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selexipag: First Global Approval.
    Scott LJ
    Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension.
    Corboz MR; Plaunt AJ; Malinin VS; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
    J Pharmacol Exp Ther; 2022 Oct; 383(1):103-116. PubMed ID: 36507843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution.
    Yanaka K; Guillien A; Soumagne T; Benet J; Piliero N; Picard F; Pison C; Sitbon O; Bouvaist H; Degano B
    Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32108046
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.